{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:12:57Z","timestamp":1767910377665,"version":"3.49.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to investigate the clinical characteristics, drug resistance patterns, and prognosis of CRKP-infected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study evaluated in patients with carbapenemase-producing CRKP infection diagnosed through bacteriological evidence and clinical criteria over a 12-month period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      KPC-producing\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      represented 1.16% of all\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      infections, the average patient age was 62.3\u202f\u00b1\u202f20.2\u202fyears. Lung infection (58%) was the most common site, followed by bloodstream infection (22%) and urinary tract (11%) infections; 86% were nosocomial. Common comorbidities included cerebrovascular disease\/cerebral infarction (23%), lung disease (16%), hematologic diseases\/malignancies (12%), and viral pneumonia (12%). KPC-Kp exhibited high resistance (&amp;gt;90%) to most tested antibiotics (including cephalosporins, piperacillin\/tazobactam, fluoroquinolones, aztreonam, and carbapenems). Significantly lower resistance was observed only to tigecycline (5.1%) and ceftazidime-avibactam (CAZ-AVI) (4.3%). Non-KPC strains (NDM\/VIM\/OXA-48;\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f48) showed lower resistance (&amp;lt;50%) to several agents and minimal resistance to tigecycline and CAZ-AVI (0\u20131.0%); resistance differences between KPC and non-KPC groups were highly significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001). KPC-Kp infection conferred significantly higher in-hospital mortality (46%) than non-KPC infections (10.4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), with nearly half (48%) of KPC-Kp deaths occurring within 7\u202fdays of infection. CAZ-AVI usage within the KPC-Kp group did not significantly improve 28-day survival (0.450\u202f\u00b1\u202f0.132 vs. 0.573\u202f\u00b1\u202f0.076,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.317). Multivariate analysis identified significant independent risk factors for in-hospital mortality: KPC-Kp infection (OR 5.96,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), bloodstream infection (OR 8.57,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006), and ICU admission (OR 3.39,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>KPC-Kp infections demonstrated high incidence (1.16%), and severe mortality (46% in-hospital). Mortality risk was significantly elevated by KPC-Kp infection, bloodstream infection, and ICU admission, underscoring critical clinical threats.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2025.1668530","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:26:59Z","timestamp":1761283619000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical epidemiology and prognostic factors in patients with KPC-producing K. pneumoniae infections: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Qiangsheng","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuejuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/antibiotics12020234","article-title":"Carbapenem-resistant Klebsiella pneumoniae: virulence factors, molecular epidemiology and latest updates in treatment options","volume":"12","author":"Karampatakis","year":"2023","journal-title":"Antibiotics"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","article-title":"Multi-drug resistant organism network investigators. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/s41564-019-0492-8","article-title":"Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread","volume":"4","author":"David","year":"2019","journal-title":"Nat Microbiol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41564-024-01612-1","article-title":"Carbapenem-resistant Klebsiella pneumoniae capsular types, antibiotic resistance and virulence factors in China: a longitudinal, multi-Centre study","volume":"9","author":"Hu","year":"2024","journal-title":"Nat Microbiol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e1004233","DOI":"10.1371\/journal.pmed.1004233","article-title":"Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: a systematic review of 128 articles across 30 countries","volume":"20","author":"Hu","year":"2023","journal-title":"PLoS Med"},{"key":"ref6","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e0000823","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"ofae273","DOI":"10.1093\/ofid\/ofae273","article-title":"Outcomes and predictors of mortality in patients with KPC-Kp infections treated with Meropenem Vaborbactam: an observational multicenter study","volume":"11","author":"Tumbarello","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cmi.2017.08.030","article-title":"Management of KPC-producing Klebsiella pneumoniae infections","volume":"24","author":"Bassetti","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13756-023-01331-y","article-title":"Infection with carbapenem-resistant hypervirulent Klebsiella pneumoniae: clinical, virulence and molecular epidemiological characteristics","volume":"12","author":"Li","year":"2023","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"S196","DOI":"10.1093\/cid\/ciy660","article-title":"Phenotypic and genotypic characterization of Carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012-2016)","volume":"67","author":"Wang","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1545999","DOI":"10.3389\/fcimb.2025.1545999","article-title":"Carbapenem-resistant Klebsiella pneumoniae infections in Chinese children: in vitro activities of ceftazidime-avibactam and aztreonam-avibactam against carbapenemase-producing strains in a two-center study","volume":"15","author":"Ran","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/mdr.2018.0398","article-title":"In vitro antimicrobial susceptibility differences between Carbapenem-resistant KPC-2-producing and NDM-1-producing Klebsiella pneumoniae in a teaching Hospital in Northeast China","volume":"26","author":"Lin","year":"2020","journal-title":"Microb Drug Resist"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jgar.2020.09.004","article-title":"Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China: a review over the last 10 years","volume":"23","author":"Liao","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"105833","DOI":"10.1016\/j.ijantimicag.2019.10.014","article-title":"A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections","volume":"55","author":"Agyeman","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"106075","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"102836","DOI":"10.1016\/j.jiph.2025.102836","article-title":"Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"18","author":"Lin","year":"2025","journal-title":"J Infect Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e0010724","DOI":"10.1128\/spectrum.00107-24","article-title":"Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant Klebsiella pneumoniae","volume":"12","author":"Wu","year":"2024","journal-title":"Microbiol Spectr"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12866-024-03465-4","article-title":"Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Microbiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1093\/jac\/dks316","article-title":"Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission","volume":"67","author":"Papadimitriou-Olivgeris","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1157010","DOI":"10.3389\/fcimb.2023.1157010","article-title":"Klebsiella pneumoniae bacteremia mortality: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2023","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1668530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:27:00Z","timestamp":1761283620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1668530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":24,"alternative-id":["10.3389\/fpubh.2025.1668530"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1668530","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"article-number":"1668530"}}